CARsgen Therapeutics, a Shanghai-headquartered cell therapy company listed in Hong Kong as 2171.HK, announced on June 22 that the National Medical Products Administration had approved satricabtagene autoleucel (satri-cel) — the company's autologous Claudin18.2-directed CAR-T — for Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma in patients who have failed at least two prior lines of systemic therapy. Satri-cel is the world's first CAR-T therapy ever approved anywhere for a solid tumor. The approval rests on the CT041-ST-01 Phase 2 randomized trial published in The Lancet in June 2025, in which satri-cel delivered a median progression-free survival of 3.25 months against 1.77 months for treatment of physician's choice in heavily pre-treated patients, with a manageable safety profile. The investigator team is led by Prof Lin Shen at Peking University Cancer Hospital. CARsgen shares rose roughly 7% in Hong Kong trading on the news. Earlier-line trials — adjuvant pancreatic (NCT05911217), post-surgical gastric consolidation (NCT06857786), and first-line sequential gastric (NCT07179484) — are already underway and will likely define satri-cel's next chapter.
For more than a decade, CAR-T cell therapy has lived almost entirely inside blood cancers. The first approved CAR-T — Kymriah, from Novartis, in 2017 — was for pediatric acute lymphoblastic leukemia. Every CAR-T that followed (Yescarta, Tecartus, Breyanzi, Carvykti, Abecma) was for a B-cell lymphoma, a B-cell leukemia, or a multiple myeloma. The reason is not lack of effort: it is that solid tumors, which make up roughly 90% of all cancer diagnoses and the overwhelming majority of cancer deaths, have been structurally hostile to the CAR-T mechanism.
The problem has three layers. First, finding a target on the tumor cell that is not also on healthy tissue — so the CAR-T cells do not destroy essential organs — has been hard. CD19, the target on B-cell cancers, is essentially a clean target: B cells can be replenished; stomach lining cannot. Claudin18.2, the target on satri-cel, is a more nuanced bet: it is highly expressed in gastric and pancreatic adenocarcinoma, but it does have a small footprint on normal gastric mucosa — which is why patient selection and preconditioning matter. Second, even when the CAR-T cells reach the tumor, they often fail to expand and survive in the immunosuppressive microenvironment that solid tumors build around themselves. CARsgen addresses this with a preconditioning regimen that adds low-dose nab-paclitaxel to the standard cyclophosphamide-fludarabine lymphodepletion, designed to soften the tumor stroma before the CAR-T cells arrive. Third, solid tumors are physically dense, and T cells have trouble trafficking into them. The first generation of solid-tumor CAR-T candidates failed most often on this third point — they found the antigen, expanded briefly, and then died before they could control the disease.
Satri-cel is not a complete answer to any of those three problems, but it is the first answer that cleared regulatory review in a major market. The approval is, in a meaningful sense, an existence proof: a CAR-T can be designed, manufactured, and dosed against a solid tumor antigen at commercially viable scale, in late-line patients with measurable disease, with a survival benefit large enough that a Phase 2 randomized comparison beat physician's choice. That existence proof is what every other solid-tumor CAR-T program — at CARsgen and elsewhere — will now point to when arguing their own case to regulators, investors, and hospital formulary committees.
CT041-ST-01 was a randomized, open-label, Phase 2 trial conducted at Peking University Cancer Hospital and additional Chinese sites, in patients with Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma who had progressed on at least two prior lines of systemic therapy. Patients were randomized to satri-cel (single intravenous infusion after preconditioning) or to treatment of physician's choice, which typically meant irinotecan, paclitaxel, or docetaxel with or without ramucirumab.
The primary efficacy readout, median progression-free survival, was 3.25 months in the satri-cel arm against 1.77 months in the control arm — a 1.48-month absolute improvement, a hazard ratio in the same range reported in the publication, and statistically significant on the trial's pre-specified analysis. The objective response rate was higher in the satri-cel arm than in the chemotherapy control arm. The safety profile was characterized as manageable: cytokine release syndrome (CRS) was the most common serious adverse event, predominantly grade 1-2, with grade 3 or higher CRS in a small minority of patients — broadly consistent with the safety experience of CAR-T in liquid tumors. The trial design and patient population are consistent with what the NMPA Center for Drug Evaluation reviewed in granting the approval.
For non-oncologists reading the numbers: a 3.25-month median PFS in third-line gastric cancer is a clinically meaningful signal, not a home run. Late-line gastric cancer is one of the highest-mortality settings in solid tumor oncology — historical median overall survival in patients who have failed two prior lines is roughly five to six months with chemotherapy alone. Satri-cel's data sit in the upper end of what late-line gastric cancer therapy has ever produced. Prof Lin Shen's own summary in the press release was that the previous treatment options for these patients "were extremely limited and the prognosis was very poor," and that satri-cel "provides us with a novel and effective therapeutic weapon" — a measured statement from an investigator who has run dozens of gastric cancer trials and is not given to hyperbole.
Three caveats are worth flagging. First, the Phase 2 comparison arm was physician's choice, not an active competitor such as trifluridine/tipiracil or a checkpoint inhibitor — both of which have data in this setting. The FDA approval of checkpoint inhibitors in late-line gastric cancer happened years ago, and zolbetuximab (the anti-Claudin18.2 antibody from Astellas, brand name Vyloy) was approved in 2024 for first-line Claudin18.2-positive, HER2-negative gastric cancer. Satri-cel will likely be used in sequence with these drugs rather than as a replacement. Second, overall survival data with longer follow-up are still maturing; PFS is a surrogate that often but not always translates. Third, the durability of CAR-T-mediated remissions in solid tumors is still an open question — in liquid tumors, a subset of patients achieves years of disease control from a single infusion, but solid-tumor CAR-T remission durations have historically been shorter. We will not know the tail of the curve for satri-cel for at least another two years.
The NMPA label for satri-cel is precise. To be a candidate for commercial satri-cel, a patient must meet all of the following criteria:
Patients who do not fit the biomarker profile — HER2-positive, Claudin18.2-negative, or squamous histology — have no benefit from satri-cel and should not pursue it. International patients considering satri-cel should arrange for tumor tissue (paraffin block or unstained slides) and a pathology report in English before traveling; the receiving center will repeat the Claudin18.2 IHC and HER2 testing in its own lab to confirm eligibility. CARsgen's commercial protocol is set up to handle this — but it is faster and cheaper if the patient arrives with the slides already cut.
Satri-cel is manufactured in China. There is no ex-China approval as of the date of this article. International patients who want satri-cel need to travel to China for apheresis (the T-cell collection step), then wait while the cells are manufactured at CARsgen's facility, and then return for lymphodepletion and infusion. The pattern is the same one used for all NMPA-approved CAR-T products in China — Jiahui International Cancer Center, Ruijin Hospital, Fudan University Shanghai Cancer Center, and a handful of Beijing and Hangzhou centers handle commercial CAR-T apheresis and infusion for international patients on a regular basis.
For international patients whose home country has a CAR-T program for liquid tumors but not for Claudin18.2-positive gastric cancer — which today is most countries — the practical question is not whether to travel to China, but which Chinese center has apheresis, infusion, and ICU capability for CAR-T and a track record with foreign patients. The CAR-T corridor in Shanghai is the most established. Hospitals that participated in CT041-ST-01 and the related earlier-line trials will have the most refined workflow.
For international patients who do not fit the eligibility criteria for commercial satri-cel — for example, Claudin18.2-positive patients who have only had one prior line of therapy, or HER2-negative patients who are Claudin18.2-negative but want a novel solid-tumor CAR-T — the earlier-line and other-indication trials are the more relevant access path. We cover those in Section 6.
CARsgen has not publicly disclosed the China commercial list price for satri-cel. The cost picture, however, is reasonably predictable from the broader NMPA-approved CAR-T category in China: the five currently commercial CAR-T products (including the recent approvals for multiple myeloma and lymphoma) typically run in the $120,000 to $170,000 USD range for an all-in package that covers apheresis, manufacturing, lymphodepletion, infusion, and 28-day post-infusion monitoring. Satri-cel is unlikely to be priced materially above that band — the clinical scenario is third-line gastric cancer, where the willingness-to-pay benchmark is chemotherapy regimens costing $5,000 to $15,000 per cycle, and the patient population is not as large as myeloma or diffuse large B-cell lymphoma.
| Product / Setting | Indication | Country | Approximate All-In Cost |
|---|---|---|---|
| Satri-cel (CARsgen) | Claudin18.2+ gastric / GEJ, 3L+ | China (NMPA approved) | $120K–$170K (est.) |
| Yescarta (Kite/Gilead) | DLBCL, 2L+ | United States (FDA) | $424K (therapy alone) |
| Kymriah (Novartis) | DLBCL / ALL | United States (FDA) | $373K–$475K |
| Carvykti (Janssen / Legend) | Myeloma, 2L+ | United States (FDA) | $525K+ |
| Relmacabtagene (JW Therapeutics) | DLBCL, 3L+ | China (NMPA) | $120K–$170K |
| Equecabtagene (JW Therapeutics / IASO) | Myeloma, 4L+ | China (NMPA) | $120K–$170K |
| Vyloy (Astellas, zolbetuximab) | Claudin18.2+ gastric, 1L | Global (FDA / EMA / PMDA) | $150K–$200K / year |
| Trifluridine/tipiracil (Lonsurf) | Gastric, 3L+ | Global | $10K–$20K / cycle |
The relevant US comparison is not a CAR-T (none is approved in the US for solid tumors), but zolbetuximab (Vyloy), which targets the same Claudin18.2 antigen but is an antibody rather than a CAR-T. Vyloy was approved by the FDA in October 2024 for first-line Claudin18.2-positive, HER2-negative gastric cancer, in combination with chemotherapy. US list pricing for Vyloy has been reported in the $150,000 to $200,000 per year range, before infusion and supportive care. Satri-cel sits roughly in the same order of magnitude for cost, with the added consideration that the CAR-T mechanism is a single infusion rather than ongoing therapy — but with the offset that manufacturing turnaround adds 4-6 weeks and requires a China trip.
International insurance coverage for satri-cel is, as of the date of this article, mostly theoretical. The product is not yet approved by the FDA, the EMA, or any other major ex-China regulator, so the standard cross-border insurance pathway (FDA approval → insurance formulary inclusion → medical tourism rider coverage) does not yet apply. Self-pay remains the dominant pathway for international patients. Some patients use Hong Kong-based or Singapore-based medical concierge firms that negotiate package pricing with Shanghai centers; the package typically includes the treating center's CAR-T clinical team, the apheresis slot, the manufacturing slot, ICU-capable monitoring, English-language coordination, and a 30-90 day post-infusion follow-up. Total package costs in the $150,000 to $200,000 range, depending on the center, the length of stay, and whether ICU time is required, are reasonable expectations.
The commercial label is third-line and beyond. The next set of clinical questions is whether satri-cel works better earlier in the disease, whether it works for other Claudin18.2-positive tumors, and whether combinations can deepen or extend responses. CARsgen and collaborating investigators have already opened trials in each of these directions:
| Trial | Phase | Indication | Setting | Identifier |
|---|---|---|---|---|
| CT041-ST-01 (the registration trial) | 2 | Gastric / GEJ, 3L+ | Metastatic, randomized vs TPC | Published in The Lancet 2025 |
| Satri-cel adjuvant pancreatic | 1 | Pancreatic adenocarcinoma, post-resection | Adjuvant, high-risk | NCT05911217 |
| Satri-cel consolidation gastric | Investigator-initiated | Resected gastric / GEJ | Post-adjuvant consolidation | NCT06857786 |
| Satri-cel 1L sequential gastric | Investigator-initiated | Advanced gastric / GEJ | Sequential after first-line chemo | NCT07179484 |
For international patients, these trials matter because they offer a different access pathway: instead of self-paying for the commercial product, patients can enroll in a clinical trial and receive satri-cel at no cost, in exchange for meeting the trial's eligibility criteria and accepting the data-collection and follow-up obligations. The trade-off is that trial enrollment is more restrictive (eligibility is tighter than the commercial label), and trial slots are limited. International patients interested in a trial should expect to provide pathology slides for central biomarker confirmation, recent imaging, and full medical history in English, and to commit to follow-up visits at the trial site for at least 12 months post-infusion.
Two specific trial-related access paths deserve highlighting. First, the pancreatic adjuvant trial (NCT05911217) is open to patients with resected pancreatic adenocarcinoma at high risk of recurrence — a setting where the standard of care is chemotherapy alone, and where a Claudin18.2-directed CAR-T could plausibly reduce recurrence risk. Claudin18.2 is expressed in a substantial fraction of pancreatic ductal adenocarcinomas, so this trial could meaningfully expand satri-cel's reach. Second, the first-line sequential gastric trial (NCT07179484) is testing satri-cel after first-line chemotherapy in patients who have not yet progressed — the clinical hypothesis is that earlier CAR-T intervention, when tumor burden is lower and immune function is more intact, could produce deeper and longer remissions than the third-line setting where the registration data were generated. Long-term follow-up data on this trial are expected to read out at ASCO and ESMO over the next 24-36 months.
CARsgen has also disclosed an exploratory collaboration with Moderna — announced in 2023 — to evaluate the combination of satri-cel with Moderna's Claudin18.2 mRNA cancer vaccine. There has been no public update from the partners on this program since the initial announcement, and we are not aware of any active combination trial enrolling patients as of this article's date.
Third-line and beyond gastric cancer is a small global market in absolute terms — perhaps 50,000 to 80,000 patients per year worldwide fall into the eligible category after second-line failure — but it is a setting where options have been very thin. For most of the past decade, the standard third-line options were trifluridine/tipiracil (Lonsurf) and paclitaxel/ramucirumab, both of which deliver median overall survival in the five-to-seven-month range. The Claudin18.2-targeted antibody zolbetuximab, approved in 2024 in the United States for first-line use, has begun to displace chemotherapy at the front of the treatment sequence, but it does not currently have a label for third-line or refractory disease. Immune checkpoint inhibitors (nivolumab, pembrolizumab) work for the roughly 10-15% of gastric cancers that are MSI-high or EBV-positive, but for the majority of gastric cancers — the Claudin18.2-positive, HER2-negative, MSS, PD-L1-low majority — checkpoint inhibitors have modest single-agent activity and have not displaced chemotherapy.
Satri-cel's entry into this setting creates a sequencing question that oncologists will be working out over the next two years. The most likely sequence, based on the current data, is: first-line chemotherapy + zolbetuximab (for Claudin18.2+ patients); second-line paclitaxel/ramucirumab; third-line satri-cel — for patients who are still Claudin18.2-positive, still HER2-negative, and still fit for apheresis and lymphodepletion. The sequencing could change if the earlier-line trials (CT041 adjuvant, 1L sequential) read out positively, in which case satri-cel could move up the treatment algorithm. CARsgen's commercial strategy appears to be exactly that — establish the third-line indication first, then file for label expansion as the earlier-line data come in.
The competitive field for solid-tumor CAR-T is also worth noting. Satri-cel is the first to reach approval, but it is not the only one in development. CARsgen has earlier-stage Claudin18.2 CAR-T constructs and is exploring combinations with checkpoint inhibitors and antibody-drug conjugates. Other Chinese biotechs (Carsgen competitors include Pharchoice Therapeutics, Gracell, and a handful of earlier-stage players) are pursuing Claudin18.2 and adjacent antigens (GPC3 for hepatocellular carcinoma, claudin 6 for testicular and ovarian cancer, mesothelin for pancreatic cancer). The US-based Claudin18.2 CAR-T programs (at Bristol Myers Squibb, AstraZeneca, and several biotechs) are in earlier stages and will likely take 3-5 years to reach approval, if they do. For now, China's lead in solid-tumor CAR-T — driven by cheaper manufacturing, faster trial enrollment in gastric cancer, and a regulatory pathway that prioritizes unmet medical need — is real.
If you or a family member is considering satri-cel as a treatment option, here is a practical sequence of steps, in approximate order of priority.
First, confirm the biomarker profile. Pull the original pathology report (the IHC and any FISH or next-generation sequencing) from the hospital that did the original biopsy or resection. You are looking for two facts: (a) is the tumor Claudin18.2-positive, and at what intensity and percentage, and (b) is the tumor HER2-negative. If the original report does not include Claudin18.2, the receiving center in Shanghai will run the test, but it adds 1-2 weeks and additional cost. Some hospitals in Hong Kong, Singapore, and a few large US centers will run the test on paraffin blocks shipped internationally — ask the treating team in Shanghai which specific antibody clone and scoring system they use before sending slides.
Second, confirm the prior-therapy count. Satri-cel's label requires failure of at least two prior systemic lines. If the patient has had only one prior line, they are not commercial-eligible but may be trial-eligible (the 1L sequential trial NCT07179484 or the consolidation trial NCT06857786). Keep a written chronology of every chemotherapy regimen, every targeted agent, and every immunotherapy dose — including start date, end date, and best response.
Third, identify the treating center. Centers that participated in CT041-ST-01 and the follow-on trials are the most familiar with satri-cel's logistics. Peking University Cancer Hospital in Beijing (Prof Lin Shen's center) and several Shanghai centers are the obvious starting points. Most international patients will be seen at a Shanghai center for the apheresis / manufacturing / infusion sequence, with Prof Shen's team available for consultative review. A bilingual case manager — either in-house at the treating center or through an experienced medical concierge firm — makes the process materially easier.
Fourth, plan the timeline and budget. Plan for a 9-12 week stay in China in total — including pre-apheresis workup, the apheresis procedure, the manufacturing window (during which the patient can return home briefly), the lymphodepletion / infusion / monitoring period, and the first 30-day post-discharge follow-up. The all-in cost is in the $150,000 to $200,000 range, depending on the center and any complications. International insurance coverage is unlikely at this point; self-pay is the standard pathway.
Fifth, consider trial options seriously. For patients who are Claudin18.2+ but not in the third-line setting — earlier in the disease, or with resected disease — the ongoing trials are the more relevant option. Trial enrollment removes the cost barrier and gives access to the same product, with the trade-off of more restrictive eligibility and a longer follow-up commitment. We can help identify which trial currently has open enrollment for a specific patient profile.
Sixth, manage expectations. Satri-cel is not curative for most patients. The Phase 2 data show a meaningful PFS improvement over chemotherapy in heavily pre-treated patients, but median PFS of 3.25 months is not a durable remission for the majority. The realistic goal is meaningful disease control with improved quality of life — which, for patients in this setting, is a real win. A subset of patients will do better; we will not know who they are until longer follow-up is published.
Working through whether satri-cel is the right option for a specific case?
We can connect you with Shanghai centers that have apheresis, manufacturing, and infusion capacity for Claudin18.2 CAR-T, review a pathology report for biomarker eligibility, and map the commercial-versus-trial access path for a specific patient's prior-therapy history.
Contact us for a case reviewSatri-cel is the second 2026 milestone for Chinese CAR-T in two months. Earlier in the spring, Akeso's gumokimab (a bispecific for autoimmune disease) and Hengrui's trastuzumab rezetecan (an ADC for colorectal cancer) both received NMPA approval on the strength of late-line data in settings where the global standard of care had been stagnant. Each of these approvals follows the same pattern: a Chinese biotech runs a confirmatory randomized trial in China, publishes in a top-five journal, files with NMPA, and receives approval — typically 12-24 months ahead of the same product reaching FDA, EMA, or PMDA approval. The result is that international patients who cannot wait for FDA approval, or who cannot afford US list prices, increasingly have a viable access path through China.
The pattern is not unique to cell therapy. Chinese biotechs are now the dominant source of new bispecific antibodies, ADCs, and CAR-T candidates in many disease settings. The cost structure is the underlying driver: clinical trials in China enroll faster (large gastric and esophageal cancer populations, plus government-supported hospital infrastructure for cell therapy), manufacturing is cheaper (the CDMO ecosystem in Shanghai, Suzhou, and Guangzhou can produce autologous CAR-T at a fraction of US cost), and the regulatory pathway under the NMPA's Breakthrough Therapy Designation and Priority Review programs is meaningfully faster than the equivalent FDA pathways. Satri-cel is the clearest example of the resulting global lead: there is no equivalent Claudin18.2 CAR-T in late-stage trials anywhere else, and the next two to three years of solid-tumor CAR-T approvals globally will likely come from Chinese biotechs.
For international patients considering medical travel to China for cell therapy specifically — and for satri-cel as the most concrete current example — the practical question is not whether China can deliver the therapy (it can, and it is the only place that can as of June 2026), but which center, which access pathway (commercial versus trial), and which logistics setup will give a specific patient the best outcome at a manageable cost. That is the work the China Hospitals Guide team does every week — case review, center matching, and travel logistics for international patients seeking cell therapy, complex oncology, and other advanced treatments in China.